VERA
Vera Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 23 ▼ 7 insiders sell $1.4M at $41.98
- Feb 23 ▼ Seven corporate insiders at Vera Therapeutics, including the CEO, CF…
- Apr 14 ▼ 1 insider sell $1.0M at $44.05
- May 12 ▼ 1 insider sell $679.7K at $36.74
- Jun 23 ▼ 1 insider sell $701.8K at $37.93
- Jul 7 ▼ 1 insider sell $2.0M at $42.30
- Sep 2 ▼ 1 insider sell $649.6K at $35.12
- Sep 15 ▼ 1 insider sell $684.5K at $37.00
- Sep 15 ▲ Vera Therapeutics announced that TRUTAKNA (atacicept-vymj) met all p…
- Oct 12 Leerink Partners initiates
- Oct 22 ▲ Vera Therapeutics announced positive final efficacy results from the…
- Oct 22 FDA: Vera Therapeutics Announces Positive ORIGIN 3 Final Effica…
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $7.1M.
- InstitutionsBULLISH
Q3 2026: 31 added (0 new), 13 trimmed or exited.
- AnalystsBULLISH
17 of 20 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$1.536 → −$1.408 over 90 days. 1 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −10.6% to 12.14M shares. 8.5 days to cover, ≈16.8% of shares.
- TrendRANGE
10% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| DEUTSCHE BANK AG\ | ADD | $68.8M |
| Pictet Asset Management Holding SA | ADD | $59.4M |
| Qube Research & Technologies Ltd | TRIM | $25.6M |
| MORGAN STANLEY | NEAR_EXIT | $22.2M |
| UBS Group AG | DOUBLED | $16.9M |
| VOYA INVESTMENT MANAGEMENT LLC | TRIM | $13.6M |
| Jump Financial, LLC | ADD | $7.6M |
| Nuveen, LLC | TRIM | $6.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analystsPrice is below the lowest target. Median implies +167%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Wedbush MAINTAIN | Neutral |
| Nov 6, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 12, 2026 | Leerink Partners INITIATE | Market Perform |
| Sep 8, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 17, 2026 | Wedbush REITERATE | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Fordyce Marshall PRESIDENT AND CEO Sep 15, 2026 | EXERCISE | $53.6K |
Fordyce Marshall PRESIDENT AND CEO Sep 15, 2026 | SELL | $684.5K |
Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR Sep 11, 2026 | EXERCISE | $19.7K |
Fordyce Marshall PRESIDENT AND CEO Sep 2, 2026 | SELL | $649.6K |
Fordyce Marshall PRESIDENT AND CEO Sep 2, 2026 | EXERCISE | $53.6K |
Boman Nancy Lee Chief Regulatory Officer Aug 3, 2026 | AWARD | 44,987 sh |
Boman Nancy Lee Chief Regulatory Officer Aug 3, 2026 | AWARD | 63,011 sh |
Fordyce Marshall PRESIDENT AND CEO Jul 7, 2026 | SELL | $95.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.41 | -$2.16–-$1.11 | +8.6% | $22.0M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$5.95 | -$6.61–-$5.65 | +4.8% | $31.2M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
23 filings · 2 press releases · 6 bullish · 7 bearish · 2 mixed · 8 neutral- NEUTRAL SC 13G/ANov 16, 2026
T. Rowe Price Associates disclosed a 3.8% passive stake in Vera Therapeutics as of September 30, 2026, holding 2,753,148 shares. This is an amendment to a prior filing, indicating a reduction from the 4.0% stake reported in the previous period.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Avoro Capital Advisors disclosed a 7.82% passive stake in Vera Therapeutics as of September 30, 2026, holding 5,635,000 shares. This is an amendment to a prior filing, confirming a reduction from the 9.71% stake reported by Deep Track Capital in the same period, though Avoro's prior stake level…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Deep Track Capital disclosed a 9.71% passive stake in Vera Therapeutics as of September 30, 2026, up from a prior filing that showed no stake. The 7 million shares held represent a new position for this filer.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 10, 2026
State Street Corp disclosed a 4.6% passive stake in Vera Therapeutics as of September 30, 2026…
State Street's passive 4.6% stake is a routine index-fund-level holding. Monitor for any future 13D conversion or material changes in position size, but no near-term activist pressure is expected.
All VERA filing & press-release reports (25)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G reportNov 10, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- INST-CLUSTER reportNov 3, 2026
- PRESS-RELEASE reportOct 22, 2026
- 8-K reportSep 15, 2026
- 8-K reportAug 10, 2026
- PRESS-RELEASE reportAug 10, 2026
- 8-K reportJul 9, 2026
- 8-K reportJul 7, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 2, 2026
- PRESS-RELEASE reportJun 2, 2026
- 8-K reportMay 7, 2026
- 8-K reportFeb 26, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026